Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor-Induced...

Area of Science:

• Oncology
• Rheumatology
• Immunology

Background:

• Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment by targeting PD-1/PD-L1 and CTLA-4 pathways.
• ICIs disrupt immune tolerance, leading to immune-related adverse events (irAEs) that manifest as de novo autoimmune and inflammatory syndromes.
• These irAEs often mimic established rheumatic diseases, posing a significant clinical challenge for oncologists and rheumatologists.

Purpose of the Study:

• To explore the rheumatologic phenotype of ICI-induced toxicities.
• To emphasize the need for targeted, mechanism-driven therapies over broad-spectrum glucocorticoids for irAE management.
• To review current clinical trials and discuss the efficacy of repurposed traditional disease-modifying antirheumatic drugs and advanced biologics for steroid-refractory irAEs.

Main Methods:

• Review of current clinical trials investigating repurposed traditional disease-modifying antirheumatic drugs and advanced biologics.
• Analysis of the efficacy and safety of specific agents like TNF-alpha inhibitors, IL-6 receptor antagonists, and JAK inhibitors in steroid-refractory irAEs.
• Exploration of molecular commonalities between idiopathic autoimmune diseases and ICI-induced inflammation.

Main Results:

• ICI-induced irAEs present a unique rheumatologic phenotype, frequently requiring rheumatologist intervention.
• Targeted therapies, including TNF-alpha inhibitors, IL-6 receptor antagonists, and JAK inhibitors, show promise in managing steroid-refractory irAEs.
• Understanding molecular commonalities may guide future treatment strategies.

Conclusions:

• The growing use of ICIs necessitates a shift towards targeted irAE management to preserve antitumor efficacy.
• Standardized grading and treatment algorithms for rheumatologic irAEs are crucial.
• Collaborative research is essential to differentiate immunotherapy toxicities from oncological benefits and optimize patient care.